An open label phase II study evaluating first-line EGFR tyrosine kinase inhibitor erlotinib in non-small cell lung cancer patients with tumors showing high EGFR gene copy number

BACKGROUND: First-line treatment with epidermal growth factor receptor (EGFR) inhibitors in NSCLC is effective in patients with activating EGFR mutations. The activity of erlotinib in patients harboring high EGFR gene copy number has been considered debatable. PATIENTS AND METHODS: A multicenter, op...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Oncotarget
मुख्य लेखकों: Szutowicz-Zielinska, Ewa, Konopa, Krzysztof, Kowalczyk, Anna, Suszko-Kazarnowicz, Malgorzata, Duchnowska, Renata, Szczesna, Aleksandra, Ratajska, Magdalena, Sowa, Aleksander, Limon, Janusz, Biernat, Wojciech, Burzykowski, Tomasz, Jassem, Jacek, Dziadziuszko, Rafal
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: Impact Journals LLC 2016
विषय:
Clinical Research Paper
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC5370039/
https://ncbi.nlm.nih.gov/pubmed/27924059
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.13793
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन